BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 18690096)

  • 1. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.
    Stemmler HJ; Mengele K; Schmitt M; Harbeck N; Laessig D; Herrmann KA; Schaffer P; Heinemann V
    Anticancer Drugs; 2008 Sep; 19(8):832-6. PubMed ID: 18690096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.
    Stemmler HJ; Schmitt M; Harbeck N; Willems A; Bernhard H; Lässig D; Schoenberg S; Heinemann V
    Oncol Rep; 2006 May; 15(5):1373-7. PubMed ID: 16596213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.
    Fizazi K; Asselain B; Vincent-Salomon A; Jouve M; Dieras V; Palangie T; Beuzeboc P; Dorval T; Pouillart P
    Cancer; 1996 Apr; 77(7):1315-23. PubMed ID: 8608509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab.
    Oliveira M; Braga S; Passos-Coelho JL; Fonseca R; Oliveira J
    Breast Cancer Res Treat; 2011 Jun; 127(3):841-4. PubMed ID: 21369716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis.
    Mego M; Sycova-Mila Z; Obertova J; Rajec J; Liskova S; Palacka P; Porsok S; Mardiak J
    Breast; 2011 Oct; 20(5):478-80. PubMed ID: 21700455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report.
    Shigekawa T; Takeuchi H; Misumi M; Matsuura K; Sano H; Fujiuchi N; Okubo K; Osaki A; Aogi K; Saeki T
    Breast Cancer; 2009; 16(1):88-92. PubMed ID: 18478315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis.
    Laufman LR; Forsthoefel KF
    Clin Breast Cancer; 2001 Oct; 2(3):235. PubMed ID: 11899418
    [No Abstract]   [Full Text] [Related]  

  • 8. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
    Bendell JC; Domchek SM; Burstein HJ; Harris L; Younger J; Kuter I; Bunnell C; Rue M; Gelman R; Winer E
    Cancer; 2003 Jun; 97(12):2972-7. PubMed ID: 12784331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intrathecal methotrexate chemotherapy for leptomeningeal carcinomatosis].
    Kullmann T; Gauthier H; le Maignan C; Szabó A; Culine S
    Orv Hetil; 2012 Sep; 153(35):1385-8. PubMed ID: 22935431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
    Glück S; Castrellon A
    Am J Ther; 2009; 16(6):585-90. PubMed ID: 19287304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrathecal chemotherapy in carcinomatous meningitis from breast cancer.
    Orlando L; Curigliano G; Colleoni M; Fazio N; Nole F; Martinelli G; Cinieri S; Graffeo R; Peruzzotti G; Goldhirsch A
    Anticancer Res; 2002; 22(5):3057-9. PubMed ID: 12530042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrathecal chemotherapy for patients with meningeal carcinomatosis.
    Yoshida S; Morii K
    Surg Neurol; 2005 Jan; 63(1):52-5; discussion 55. PubMed ID: 15639526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab.
    Platini C; Long J; Walter S
    Lancet Oncol; 2006 Sep; 7(9):778-80. PubMed ID: 16945774
    [No Abstract]   [Full Text] [Related]  

  • 14. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.
    García-Sáenz JA; Martín M; Puente J; López-Tarruella S; Casado A; Moreno F; Grande E; Díaz-Rubio E
    Clin Breast Cancer; 2005 Oct; 6(4):325-9. PubMed ID: 16277882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intrathecal methotrexate in breast cancer meningeal carcinomatosis - Experience with a new administration schedule].
    Cochereau D; Da Costa S; Le Maignan C; Gauthier H; Cochereau J; Espié M; Giacchetti S; Teixeira L
    Bull Cancer; 2016 May; 103(5):444-54. PubMed ID: 26987841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
    Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
    Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Case of leptomeningeal carcinomatosis effectively treated with intrathecal chemotherapy using ventriculoperitoneal shunt].
    Miura M; Iijima N; Hayashida K; Kitazawa K; Ishii K; Ohara S
    Rinsho Shinkeigaku; 2006 Jun; 46(6):404-9. PubMed ID: 16986702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.
    Stemmler HJ; Schmitt M; Willems A; Bernhard H; Harbeck N; Heinemann V
    Anticancer Drugs; 2007 Jan; 18(1):23-8. PubMed ID: 17159499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases.
    Martens J; Venuturumilli P; Corbets L; Bestul D
    Acta Oncol; 2013 Jan; 52(1):175-8. PubMed ID: 22655969
    [No Abstract]   [Full Text] [Related]  

  • 20. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.